Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pragmatic, Multicenter, Double-Blind Evaluation of Circulating Cancer-Associated Macrophage-Like Cells for Detection of Cancer in Indeterminate Pulmonary Nodules.

JCO precision oncology·2026
Same author

Impact of race and acculturation on lung cancer screening eligibility: a multicenter lung cancer cohort study.

American journal of respiratory and critical care medicine·2026
Same author

The Digital Information Environment of Lung Cancer and Lung Cancer Screening: Protocol for a Cross-Platform Social Media Content Analysis.

JMIR research protocols·2026
Same author

Mindful self-compassion to reduce stigma among individuals diagnosed with lung cancer (MSC-LC): a pilot study protocol for a parallel-group, randomized controlled trial.

Pilot and feasibility studies·2026
Same author

Leveraging Social Media to Achieve Population-Level Reach of Lung Cancer Screening-Eligible Individuals: A RE-AIM Framework Perspective.

Journal of medical Internet research·2026
Same author

Correction: Leveraging Social Media to Achieve Population-Level Reach of Lung Cancer Screening-Eligible Individuals: A RE-AIM Framework Perspective.

Journal of medical Internet research·2026

Related Experiment Video

Updated: Jun 14, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening.

Lindsey B Cotton1, Peter B Bach1, Chris Cisar1

  • 1DELFI Diagnostics, Inc., Baltimore, MD 21224, USA.

Journal of Clinical Medicine
|August 29, 2024
PubMed
Summary

Lung cancer screening uptake is low due to access issues. A new blood test analyzing cell-free DNA fragmentation may improve early lung cancer detection and screening adherence.

Keywords:
DELFINSCLCUSPSTFblood-based testingcell-free DNAfragmentomicsliquid biopsylow-dose computed tomographylung cancer screeningscreening adherence

More Related Videos

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K
Detection of Lung Tumor Progression in Mice by Ultrasound Imaging
04:43

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging

Published on: February 27, 2020

6.7K

Related Experiment Videos

Last Updated: Jun 14, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K
Detection of Lung Tumor Progression in Mice by Ultrasound Imaging
04:43

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging

Published on: February 27, 2020

6.7K

Area of Science:

  • Oncology
  • Genomics
  • Public Health

Background:

  • Lung cancer, especially non-small cell lung cancer (NSCLC), has high mortality rates globally.
  • Lung cancer screening uptake, primarily low-dose computed tomography (LDCT), remains low (around 5%) due to healthcare access inequities.
  • Personalized NSCLC management is advancing with blood-based biomarker testing.

Purpose of the Study:

  • To review the current lung cancer screening landscape.
  • To identify barriers to lung cancer screening adoption.
  • To explore the potential of a plasma whole genome fragmentome test (pWGFrag-Lung) for improving screening participation and adherence.

Main Methods:

  • Review of existing literature on lung cancer screening efficacy and uptake.
  • Analysis of obstacles contributing to low screening rates.
  • Assessment of cell-free DNA (cfDNA) fragmentation as a biomarker for early lung cancer detection.

Main Results:

  • Despite evidence supporting LDCT, screening participation is significantly limited.
  • Healthcare access inequities are a major factor hindering screening adoption.
  • Plasma whole genome fragmentome (pWGFrag-Lung) testing shows promise for early detection.

Conclusions:

  • Addressing access barriers is crucial for increasing lung cancer screening rates.
  • Novel blood-based biomarkers like pWGFrag-Lung could enhance early lung cancer detection.
  • Improved screening participation and adherence are essential for reducing lung cancer mortality.